The Michigan Radiation Oncology Quality Consortium (MROQC) is a Blue Cross Blue Shield of Michigan-Blue Care Network (BCBSM-BCN) sponsored Collaborative Quality Initiative (CQI).
Molecular testing is an integral component of multidisciplinary management of breast cancer. Recent evidence underscores the importance of molecular assays in radiation therapy decision making.
There is a significant gap in the knowledge and practice of integrating novel systemic therapies with radiotherapy in breast cancer management, particularly due to limited clinical trial data on their combined use.
Brachytherapy is an invaluable tool in the radiation oncologist's toolbox, but the perceived proficiency among residents has been variable and there is great diversity in how programs deliver brachytherapy.
With technological advances re-irradiation has rapidly become common and an important part of cancer management to new or recurrent tumors, yet is clinically challenging given risks of serious toxicity from cumulative doses.
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.
Facebook
X
LinkedIn
Forward
